Search

Your search keyword '"Ruggieri, B"' showing total 2 results
Start Over Author "Ruggieri, B" Topic aspirin
2 results on '"Ruggieri, B"'

1. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance.

Author

Renda G, Zurro M, Malatesta G, Ruggieri B, and De Caterina R

Subjects
Adenosine Diphosphate pharmacology, Adult, Arachidonic Acid pharmacology, Blood Platelets physiology, Collagen pharmacology, Drug Resistance, Female, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors pharmacology, Thromboxane B2 blood, Young Adult, Aspirin pharmacology, Blood Platelets drug effects, Platelet Aggregation drug effects, Platelet Function Tests methods
Abstract

Background: Assays to evaluate platelet function are often interchangeably used to assess "resistance" to aspirin. We compared different platelet function assays in patients treated or untreated with aspirin., Design and Methods: Platelet function was evaluated in 162 subjects, 85 of whom were not being treated with any antiplatelet drug and 77 of whom were receiving chronic therapy with low-dose aspirin. Platelet Function Analyzer collagen/ADP- and collagen/epinephrine closure times, as well as light transmittance aggregometry in response to ADP, collagen and arachidonic acid (this last in 47 aspirin-treated patients) were determined. In 43 aspirin-treated patients, serum thromboxane B(2) levels were also measured., Results: In untreated patients, collagen/ADP- and collagen/epinephrine-closure times were correlated with each other (r=0.5, P=0.0001), but did not correlate with ADP- or collagen-induced aggregation. In patients treated with aspirin, collagen/ADP-closure time values were not different from those in untreated patients, while the collagen/epinephrine-closure time was prolonged. ADP-induced aggregation was unaffected by aspirin, while collagen-induced aggregation was reduced. Arachidonic acid-induced aggregation was almost completely suppressed (% maximum light transmittance aggregometry =5 ± 13%). There was, however, no correlation between the various platelet function tests. Serum thromboxane B(2), an index of platelet cyclooxygenase-1 activity, was almost completely suppressed (down to 8 ± 17 ng/mL) in treated patients, and was not correlated with arachidonic acid-, ADP- and collagen-induced aggregation or with collagen/ADP-closure time, but was inversely correlated with collagen/epinephrine-closure time., Conclusions: There is a high heterogeneity of results of tests evaluating inhibition of platelet function by aspirin, and the results of functional tests do not match biochemical measurement of cyclooxygenase-1 activity. Extreme caution should, therefore, be used in defining "resistance" to aspirin on the basis of the results of these tests.

Published
2010
Full Text
View/download PDF

2. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper

Author

Patti, G, DE CATERINA, Raffaele, Abbate, R, Andreotti, F, Biasucci, L. M, Calabrò, P, Cioni, G, Davi', Giovanni, Di Sciascio, G, Golia, E, Golino, P, Malatesta, G, Mangiacapra, F, Marcucci, R, Nusca, A, Parato, V. M, Pengo, V, Prisco, D, Pulcinelli, F, Renda, Giulia, Ricottini, E, Ruggieri, B, Santilli, Francesca, Sofi, F, Zimarino, M, Working Group on Thrombosis of the Italian Society of Cardiology, Patti, G, De Caterina, R, Abbate, R, Andreotti, F, Biasucci, Lm, Calabro', Paolo, Cioni, G, Davì, G, Di Sciascio, G, Golia, E, Golino, Paolo, Malatesta, G, Mangiacapra, F, Marcucci, R, Nusca, A, Parato, Vm, Pengo, V, Prisco, D, Pulcinelli, F, Renda, G, Ricottini, E, Ruggieri, B, Santilli, F, Sofi, F, and Zimarino, M.

Subjects
Blood Platelets, Male, Platelets, medicine.medical_specialty, Post hoc, Platelet Function Tests, Pregnancy Complications, Cardiovascular, Hemorrhage, Body size, Risk Assessment, Cost of Illness, Pregnancy, Risk Factors, Medicine, Humans, Gender differences, Platelet, Women, Intensive care medicine, Secondary prevention, Aspirin, Sex Characteristics, business.industry, Antiplatelet therapy, gender differences, platelets, antiplatelet therapy, men, thrombosis, women, Men, Thrombosis, medicine.disease, Stroke, Multiple factors, Treatment Outcome, Cardiovascular Diseases, Physical therapy, Observational study, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, business, Diabetic Angiopathies, Platelet Aggregation Inhibitors, medicine.drug
Abstract

Although the female gender is generally less represented in cardiovascular studies, observational and randomized investigations suggest that-compared with men-women may obtain different benefits from antiplatelet therapy. Multiple factors, including hormonal mechanisms and differences in platelet biology, might contribute to such apparent gender peculiarities. The thrombotic and bleeding risks, as well as outcomes after a cardiovascular event, appear to differ between genders, partly in relation to differences in age, comorbidities and body size. Equally, the benefits of antiplatelet therapy may differ in women compared with men in different vascular beds, during primary or secondary prevention and according to the type of an antiplatelet agent used. This document is an attempt to bring together current evidence, clinical practices and gaps of knowledge on gender-specific platelet function and antiplatelet therapy. On the basis of the available data, we provide suggestions on current indications of antiplatelet therapy for cardiovascular prevention in women with different clinical features; no strong recommendation may be given because the available data derive from observational studies or post hoc/subgroup analyses of randomized studies without systematic adjustments for baseline risk profiles.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results